- A clinical trial of celiprolol in type II diabetic patients with essential hypertension
-
Park SW, Chung YS, Park JO, Park SW, Lim SK, Lee HC, Huh KB
- KMID: 1700073
- J Korean Diabetes Assoc.
- 1993 Sep;17(3):307-313.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- A Clinical Study on the Antihypertensive Effect of Celiprolol
-
Lee OC, Yoon SJ, Kim JH, Chang DK, Kim JP, Kim KS, Kim JH, Im HK, Lee BH, Lee CK
- KMID: 1894904
- Korean Circ J.
- 1992 Oct;22(5):838-843.
- doi: 10.4070/kcj.1992.22.5.838
BACKGROUND: Celiprolol is a beta-adrenergic blocker characterized by selective blokade of beta1 receptors and partial agonist activity at beta2 receptors. This study was designed to evaluate the antihypertensive efficacy, metabolic... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Effect and Safety of Celiprolol in Patients with Essential Hypertension
-
Park CG, Kim YH, Park HN, Seo HS, Shim WJ, Oh DJ, Park JE, Ro YM
- KMID: 2229278
- Korean Circ J.
- 1993 Dec;23(6):907-914.
- doi: 10.4070/kcj.1993.23.6.907
BACKGROUND: Celiprolol is a new generation beta-adrenoreceptor blocking agent with intrinsic sympathomimetic activity characterized by selective blockade of beta1 receptors and partial agonist activity at beta2 receptors. This study was... -
- CITED
-
- Close
- SHARE
-
- Close
